Cholestyramine: Clinical Overview
Indications
Cholestyramine is FDA-approved primarily for hypercholesterolemia and has established off-label uses for cholestatic pruritus and bile acid diarrhea. 1
Primary Indications:
- Hypercholesterolemia: First-line bile acid sequestrant for primary type IIa hyperlipidemia and familial hypercholesterolemia when dietary measures fail 1, 2
- Cholestatic pruritus: First-line treatment for pruritus in cholestatic liver disease (e.g., primary biliary cholangitis) 3
- Bile acid diarrhea (BAD): First-line bile acid sequestrant therapy for empiric treatment 4
Dosing
Starting Dose:
Begin with 4 grams (one packet/scoop) once or twice daily 1. For bile acid diarrhea specifically, start at 2-4 g/day 4.
Titration Strategy:
Gradual dose escalation is essential to minimize gastrointestinal side effects and improve compliance 4. Increase dose slowly based on clinical response, with assessment intervals of at least 4 weeks for hypercholesterolemia 1.
Maintenance Dose:
- Standard: 8-16 grams daily (2-4 packets) divided into 2 doses 1
- Maximum: 24 grams daily (6 packets) 1
- For pruritus: 4 grams up to four times daily 3
Administration:
- Never administer dry powder—always mix with at least 2-3 ounces of water or non-carbonated beverage 1
- Can be mixed with highly fluid soups or pulpy fruits (applesauce, crushed pineapple) 1
- Space 4 hours away from other medications (especially UDCA in cholestatic disease) to avoid binding and reduced absorption 3
- Can be given 1-6 times daily, though twice daily is standard; single daily dosing may be equally effective for some patients 1, 5
Contraindications and Cautions
Avoid in:
Patients with Crohn's disease and extensive ileal involvement (>100 cm resection) should NOT receive cholestyramine due to risk of worsening steatorrhea and caloric loss 4. The consensus recommendation is against BAST use in this population.
Use with caution in:
- Complete biliary obstruction (only use in incomplete obstruction) 2
- Within 3 months of abdominal surgery (case report of intestinal obstruction) 6
- Patients requiring absorption of other critical medications
Adverse Effects
Common (High Frequency):
- Gastrointestinal effects: Foul taste (73%), nausea with bloating (18%), constipation 7
- These side effects are significantly more common than with colesevelam, which has placebo-level tolerability 4
Metabolic/Nutritional:
- Fat-soluble vitamin deficiencies (A, D, E, K)—monitor and supplement as needed 3
- Decreased 25-hydroxyvitamin D levels 6
- Folate deficiency possible even at low doses 6
- Elevated homocysteine (secondary to folate deficiency) 6
- May increase triglycerides, particularly in familial combined hyperlipidemia 7
Serious but Rare:
- Intestinal obstruction (especially post-abdominal surgery) 6
Monitoring Parameters
Baseline and Periodic Monitoring:
- Lipid panel: Total cholesterol, LDL-C, HDL-C, triglycerides (assess every 4 weeks minimum during titration) 1
- Fat-soluble vitamins (A, D, E, K) 3
- Folate levels and homocysteine 6
- Liver function tests if used for cholestatic conditions 3
- Stool frequency and consistency for bile acid diarrhea 4
Clinical Response Assessment:
- For hypercholesterolemia: Expect 15-27% reduction in LDL-cholesterol 8, 7
- For pruritus: Use visual analog scale for itch quantification 3
- For bile acid diarrhea: Monitor stool frequency, consistency (Bristol scale), and incontinence episodes 9
Key Clinical Pitfalls
Compliance Issues:
Poor long-term compliance is the major limitation—in pediatric studies, the majority discontinued medication after ~22 months despite good efficacy 7. The unpalatable nature and gastrointestinal side effects drive discontinuation.
Drug Interactions:
Critical spacing requirement: Must separate from other medications by 4 hours to prevent binding and malabsorption 3. This is particularly important for UDCA in cholestatic disease and any other essential medications.
Alternative Considerations:
Colesevelam has superior tolerability (placebo-level side effects) and easier administration (tablets vs powder), but is reserved for second-line use after cholestyramine failure due to limited experience and higher cost 4. Response rates are similar (73-74%) between agents.
Growth in Children:
Height velocity is not adversely affected in prepubertal/peripubertal children, but vitamin D supplementation should be considered and folate must be monitored 6.